Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel small molecule allosteric modulators for neurological disorders. Listed on both the SIX Swiss Exchange and the NASDAQ Capital Market under the ticker symbol ADXN, the company focuses on targeted therapeutic solutions for complex brain and central nervous system conditions.
Led by Chief Executive Officer Tim Dyer, Addex maintains a drug pipeline addressing significant unmet medical needs. The company regularly updates investors and analysts on its pipeline developments and core business initiatives.
Key Candidates in the Addex Drug Pipeline
The lead drug candidate at Addex is dipraglurant, an mGlu5 negative allosteric modulator (NAM). Research evaluates dipraglurant for brain injury recovery applications, including post-stroke and traumatic brain injury recovery.
Alongside dipraglurant, Addex has selected a GABAB positive allosteric modulator (PAM) drug candidate aimed at treating substance use disorders. This candidate has successfully completed Investigational New Drug (IND) enabling studies. Additionally, the company is developing a differentiated GABAB PAM compound designed for chronic cough treatment.
Strategic Holdings and Equity Investments
Beyond its proprietary research, Addex holds strategic interests in specialized biopharmaceutical entities. The company maintains an 8.5% equity stake in Neurosterix US Holdings LLC, a private spin-out enterprise advancing allosteric modulator programs. These include M4 PAM for schizophrenia, psychosis, and mood-related disorders, as well as mGlu7 NAM for mood disorders.
Addex has also invested in Stalicla, a private Swiss biopharmaceutical company pioneering a precision medicine approach aimed at neurodevelopmental and neuropsychiatric disorders. Through these research efforts and equity holdings, Addex continues to build its position in the neurological therapeutic sector.